Coronation Fund Managers Ltd. Boosts Stake in Danaher Corporation $DHR

Key Points

• Coronation Fund Managers increased its Danaher stake by 48.5% in Q4, buying an additional 7,639 shares to hold 23,396 shares worth about $5.356 million.
• Danaher is facing near-term headwinds — including a shareholder settlement of roughly $172.5M, several analyst price‑target cuts and a ~17.8% rise in short interest — while also pricing about €3.0B of euro‑denominated senior notes.
• On the fundamentals side, Danaher beat quarterly EPS estimates ($2.06 vs. $1.94), set FY2026 guidance of $8.35–8.55 EPS, and raised its quarterly dividend to $0.40 (annualized $1.60, ~0.9% yield).

Coronation Fund Managers Ltd. lifted its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 48.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,396 shares of the conglomerate's stock after buying an additional 7,639 shares during the period. Coronation Fund Managers Ltd.'s holdings in Danaher were worth $5,356,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Enterprise Financial Services Corp lifted its stake in shares of Danaher by 1.4% in the fourth quarter. Enterprise Financial Services Corp now owns 3,219 shares of the conglomerate's stock worth $737,000 after buying an additional 46 shares in the last quarter. Kennebec Savings Bank lifted its stake in shares of Danaher by 1.4% in the fourth quarter. Kennebec Savings Bank now owns 3,348 shares of the conglomerate's stock worth $766,000 after buying an additional 46 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Danaher by 2.6% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,870 shares of the conglomerate's stock worth $428,000 after buying an additional 47 shares in the last quarter. Kestra Private Wealth Services LLC lifted its stake in shares of Danaher by 0.3% in the third quarter. Kestra Private Wealth Services LLC now owns 15,421 shares of the conglomerate's stock worth $3,057,000 after buying an additional 48 shares in the last quarter. Finally, Norway Savings Bank lifted its stake in shares of Danaher by 0.7% in the fourth quarter. Norway Savings Bank now owns 7,063 shares of the conglomerate's stock worth $1,617,000 after buying an additional 49 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of Danaher stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $208.01, for a total transaction of $274,573.20. Following the completion of the sale, the executive vice president directly owned 5,099 shares in the company, valued at $1,060,642.99. This trade represents a 20.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on DHR shares. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of Danaher in a research note on Thursday, January 29th. Morgan Stanley reduced their target price on shares of Danaher from $270.00 to $255.00 and set an "overweight" rating on the stock in a research note on Wednesday. Wolfe Research reduced their target price on shares of Danaher from $260.00 to $230.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 8th. TD Cowen reduced their target price on shares of Danaher from $245.00 to $240.00 and set a "buy" rating on the stock in a research note on Wednesday. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $245.00 target price on shares of Danaher in a research note on Tuesday. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $242.45.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Guggenheim reiterated a Buy rating on Danaher, supporting demand-side interest from institutional buyers. Guggenheim Reaffirms Buy
• Positive Sentiment: An analyst price-target lift to $232 signals buy-side upside vs. current levels, which can support the stock if investors focus on medium-term earnings guidance. Price Target Raised to $232
• Neutral Sentiment: Danaher priced ~€3.0 billion of euro-denominated senior notes across maturities (2028–2038). This raises liquidity for operations or M&A but increases long-term debt on the balance sheet. Senior Notes Offering
• Neutral Sentiment: Coverage pieces question whether the recent share weakness makes DHR an attractive value play — useful for long-term investors but not an immediate catalyst. Valuation Article
• Negative Sentiment: Danaher agreed to settle shareholder litigation tied to its post‑pandemic outlook for about $172.5M, a direct hit to cash and a reminder of past forecasting issues; that likely pressured sentiment. Settlement Report
• Negative Sentiment: Short interest rose ~17.8% to 8.18M shares as of April 15 (≈1.3% of float; short-interest ratio ~2.5 days), indicating increased speculative/hedged bearish positioning that can amplify downward moves.
• Negative Sentiment: Morgan Stanley trimmed its price target (from $270 to $255), and UBS issued a pessimistic forecast—both moves add analyst-driven downside pressure despite differing target levels. Morgan Stanley PT Cut UBS Forecast
• Negative Sentiment: Analysts/commentary flag Danaher’s Masimo acquisition as adding long-term potential but creating near-term margin and integration pressure, a nearer-term risk to earnings momentum. Masimo Deal Commentary

Danaher Price Performance

Shares of DHR stock opened at $177.31 on Friday. Danaher Corporation has a 12 month low of $175.00 and a 12 month high of $242.80. The company has a market capitalization of $125.49 billion, a PE ratio of 34.30, a price-to-earnings-growth ratio of 2.42 and a beta of 0.95. The firm's 50-day moving average is $195.75 and its two-hundred day moving average is $213.86. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.87 and a quick ratio of 1.51.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share for the quarter, beating analysts' consensus estimates of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The business had revenue of $5.95 billion during the quarter, compared to analysts' expectations of $6 billion. During the same period last year, the business earned $1.88 earnings per share. The business's revenue for the quarter was up 3.7% on a year-over-year basis. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. Analysts predict that Danaher Corporation will post 8.43 earnings per share for the current year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 24th. Shareholders of record on Friday, March 27th were given a dividend of $0.40 per share. This is a boost from Danaher's previous quarterly dividend of $0.32. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date was Friday, March 27th. Danaher's dividend payout ratio (DPR) is 30.95%.

About Danaher

Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.